Long term inhibition of hip joint damage under tumor necrosis factor-alpha inhibitors in spondyloarthritis
- 6 September 2020
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 88, 106927
- https://doi.org/10.1016/j.intimp.2020.106927
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Hip disease in ankylosing spondylitisCurrent Opinion in Rheumatology, 2013
- Imaging in ankylosing spondylitisTherapeutic Advances in Musculoskeletal Disease, 2012
- Efficacy of etanercept in ankylosing spondylitis hip lesionsJoint Bone Spine, 2011
- Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee jointArthritis Research & Therapy, 2010
- Hip involvement in ankylosing spondylitisRheumatology, 2009
- Revision Total Hip ArthroplastyClinical Orthopaedics and Related Research, 2006
- Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathiesArthritis & Rheumatism, 2005
- Chondroprotective drugs in degenerative joint diseasesRheumatology, 2005
- Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activationAnnals Of The Rheumatic Diseases, 2002
- Histopathology of the synovial membrane of peripheral joints in ankylosing spondylitis.Annals Of The Rheumatic Diseases, 1982